Advancing Health Equity, Policy Reform. Economic Justice.
- News & Event
- Contact
Advancing Health Equity, Policy Reform. Economic Justice.
M4MM is committed to advancing cannabinoid research and real-world evidence to improve outcomes for individuals living with sickle cell disease.
M4MM’s first research collaboration partners are advancing education, awareness, and evidence-based resources for the sickle cell community.
CCDI is a leading organization dedicated to advancing sickle cell research, education, and community engagement through innovative partnerships.
PharmaSickle Visit Prep equips patients and caregivers with tools and knowledge to have informed, confident conversations with their healthcare providers.
Top peer-reviewed references highlighting cannabinoid research and therapeutic potential.
Blake, D. R., et al. (2021). Cannabis and the cannabinoids: pharmacology, toxicology, and therapeutic potential. Pharmacological Reviews, 73(2), 298-326.
Pertwee, R. G. (2018). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9- etrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology, 175(8), 1332-1348.
Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.
Whiting, P. F., et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA, 313(24), 2456-2473.
Mücke, M., et al. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, (3), CD012182.
M4MM is not providing medical advice. Consult your healthcare provider for personalized guidance.
